VAXCYTE, INC. Investment Income, Interest
VAXCYTE, INC. (PCVX) reported Investment Income, Interest of $25.75 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-05
- VAXCYTE, INC. investment income, interest for the quarter ending 2026-06-30 was $25.75M, a 17.11% decline year-over-year.
- VAXCYTE, INC. investment income, interest for the quarter ending 2026-03-31 was $26.61M, a 19.20% decline year-over-year.
- VAXCYTE, INC. investment income, interest for the quarter ending 2025-12-31 was $26.45M, a 27.45% decline year-over-year.
- VAXCYTE, INC. investment income, interest for the quarter ending 2025-09-30 was $29.26M, a 4.28% increase year-over-year.
- VAXCYTE, INC. investment income, interest for fiscal 2025 was $119.72M, a 8.84% increase from fiscal 2024.
- VAXCYTE, INC. investment income, interest for fiscal 2024 was $109.99M, a 74.85% increase from fiscal 2023.
- VAXCYTE, INC. investment income, interest for fiscal 2023 was $62.91M, a 652.84% increase from fiscal 2022.
- VAXCYTE, INC. investment income, interest for fiscal 2022 was $8.36M, a 2329.07% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $25.75M 10-Q · filed 2026-08-05 | $52.37M 10-Q · filed 2026-08-05 | $78.82M derived: sum of 3 quarters · filed 2026-08-05 | $108.08M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $26.61M 10-Q · filed 2026-05-06 | $53.06M derived: sum of 2 quarters · filed 2026-05-06 | $82.32M derived: sum of 3 quarters · filed 2026-05-06 | $113.39M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $26.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $55.71M derived: sum of 2 quarters · filed 2026-02-24 | $86.78M derived: sum of 3 quarters · filed 2026-08-05 | $119.72M 10-K · filed 2026-02-24 |
| 2025-09-30 | $29.26M 10-Q · filed 2025-11-04 | $60.33M derived: sum of 2 quarters · filed 2026-08-05 | $93.27M 10-Q · filed 2025-11-04 | $129.72M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $31.07M 10-Q · filed 2026-08-05 | $64.01M 10-Q · filed 2026-08-05 | $100.47M derived: sum of 3 quarters · filed 2026-08-05 | $128.52M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $32.94M 10-Q · filed 2026-05-06 | $69.39M derived: sum of 2 quarters · filed 2026-05-06 | $97.45M derived: sum of 3 quarters · filed 2026-05-06 | $121.26M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $36.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $64.52M derived: sum of 2 quarters · filed 2026-02-24 | $88.33M derived: sum of 3 quarters · filed 2026-02-24 | $109.99M 10-K · filed 2026-02-24 |
| 2024-09-30 | $28.06M 10-Q · filed 2025-11-04 | $51.87M derived: sum of 2 quarters · filed 2025-11-04 | $73.54M 10-Q · filed 2025-11-04 | $91.10M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $23.81M 10-Q · filed 2025-08-06 | $45.48M 10-Q · filed 2025-08-06 | $63.05M derived: sum of 3 quarters · filed 2026-02-24 | $81.54M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $21.67M 10-Q · filed 2025-05-07 | $39.23M derived: sum of 2 quarters · filed 2026-02-24 | $57.73M derived: sum of 3 quarters · filed 2026-02-24 | $74.18M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $17.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $36.06M derived: sum of 2 quarters · filed 2026-02-24 | $52.51M derived: sum of 3 quarters · filed 2026-02-24 | $62.91M 10-K · filed 2026-02-24 |
| 2023-09-30 | $18.50M 10-Q · filed 2024-11-05 | $34.95M derived: sum of 2 quarters · filed 2024-11-05 | $45.34M 10-Q · filed 2024-11-05 | $51.97M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $16.45M 10-Q · filed 2024-08-06 | $26.84M 10-Q · filed 2024-08-06 | $33.48M derived: sum of 3 quarters · filed 2025-02-25 | $34.67M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $10.39M 10-Q · filed 2024-05-08 | $17.03M derived: sum of 2 quarters · filed 2025-02-25 | $18.22M derived: sum of 3 quarters · filed 2025-02-25 | $18.61M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $6.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $7.82M derived: sum of 2 quarters · filed 2025-02-25 | $8.22M derived: sum of 3 quarters · filed 2025-02-25 | $8.36M 10-K · filed 2025-02-25 |
| 2022-09-30 | $1.19M 10-Q · filed 2023-11-06 | $1.59M derived: sum of 2 quarters · filed 2023-11-06 | $1.72M 10-Q · filed 2023-11-06 | $1.82M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $399.00K 10-Q · filed 2023-08-08 | $533.00K 10-Q · filed 2023-08-08 | $632.00K derived: sum of 3 quarters · filed 2024-02-27 | $722.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $134.00K 10-Q · filed 2023-05-08 | $233.00K derived: sum of 2 quarters · filed 2024-02-27 | $323.00K derived: sum of 3 quarters · filed 2024-02-27 | $416.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $99.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $189.00K derived: sum of 2 quarters · filed 2024-02-27 | $282.00K derived: sum of 3 quarters · filed 2024-02-27 | $344.00K 10-K · filed 2024-02-27 |
| 2021-09-30 | $90.00K 10-Q · filed 2022-11-07 | $183.00K derived: sum of 2 quarters · filed 2022-11-07 | $245.00K 10-Q · filed 2022-11-07 | $276.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $93.00K 10-Q · filed 2022-08-08 | $155.00K 10-Q · filed 2022-08-08 | $186.00K derived: sum of 3 quarters · filed 2023-02-27 | $219.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $61.00K 10-Q · filed 2022-05-09 | $93.00K derived: sum of 2 quarters · filed 2023-02-27 | $126.00K derived: sum of 3 quarters · filed 2023-02-27 | $170.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $32.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $65.00K derived: sum of 2 quarters · filed 2023-02-27 | $109.00K derived: sum of 3 quarters · filed 2023-02-27 | $244.00K 10-K · filed 2023-02-27 |
| 2020-09-30 | $33.00K 10-Q · filed 2021-11-10 | $77.00K derived: sum of 2 quarters · filed 2021-11-10 | $212.00K 10-Q · filed 2021-11-10 | $307.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $44.00K 10-Q · filed 2021-08-11 | $179.00K 10-Q · filed 2021-08-11 | $274.00K derived: sum of 3 quarters · filed 2022-02-28 | $394.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $135.00K 10-Q · filed 2021-05-11 | $230.00K derived: sum of 2 quarters · filed 2022-02-28 | $350.00K derived: sum of 3 quarters · filed 2022-02-28 | $531.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $95.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $215.00K derived: sum of 2 quarters · filed 2022-02-28 | $396.00K derived: sum of 3 quarters · filed 2022-02-28 | $632.00K 10-K · filed 2022-02-28 |
| 2019-09-30 | $120.00K 10-Q · filed 2020-11-12 | $301.00K derived: sum of 2 quarters · filed 2020-11-12 | $537.00K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $181.00K 10-Q · filed 2020-08-12 | $418.00K 10-Q · filed 2020-08-12 | ||
| 2018-12-31 | $903.00K 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |